NEWS: New Conjugate Typhoid Vaccine Is Awarded WHO Prequalification
WHO to take a big step forward in the fight against Typhoid. An Indian bioresearch company has now been granted World Health Organisation pre-qualification for their product Typbar-TCV. Typbar-TCV is a conjugate vaccine. Conjugate vaccines offer longer and stronger immunity over their polysaccharide cousins and its product has been demonstrated safe in populations as young as 6 months. Until now countries endemic with Typhoid fever, which is a bacterial infection caused by Salmonella, have relied on an old polysaccharide vaccine. The current polysaccharide vaccine can only be used from 2... Read More